Lupin settles with Depomed/Santarus for generic Glumetza
This article was originally published in Scrip
Lupin's US arm has entered into a settlement with Santarus Inc and Depomed to resolve pending patent litigation concerning the type 2 diabetes treatment, Glumetza (extended release metformin tablets) 1000mg and 500mg. Lupin believes it is the first to file an ANDA for both strengths, entitling it to 180 days of marketing exclusivity.
You may also be interested in...
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.